Clint Narver

Clint Narver, a partner at McGuireWoods and former leader at the DOJ and FDA, dives into the intricate world of pharma regulations. He sheds light on how the increasing scrutiny affects clinical trials and site management. Narver explains the responsibilities of Contract Research Organizations and the shift toward decentralized trials, emphasizing compliance. He also discusses the DOJ’s Safe Harbor policy, which encourages companies to disclose corporate crimes found during due diligence, a crucial insight for investors in the pharma services sector.